Satisfaction/Quality of Life with Rivaroxaban in SPAF (stroke prevention in atrial fibrillation) indication (SAFARI)
National, multicenter, prospective, observational, non-interventional study. The objective is to determine if the switch from Vitamin K antagonists (VKA) to Xarelto in subjects treated with VKA with issues for stroke prevention in non valvular atrial fibrillation is associated with an improvement of the treatment satisfaction after 3 months. The treatment satisfaction will be measured by the Anti Clot Treatment Scale (ACTS) score.
- Female and male subjects ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation - Who are treated with Vitamin K antagonists (VKA) with issues for at least the 4 previous weeks (issues are assessed on medical judgment) - Who start treatment with rivaroxaban to prevent stroke or non-CNS (central nervous system) systemic embolism - With anticoagulation therapy planned for at least 6 months
- Contra indication to the use of Xarelto as described in the Summary of Product Characteristics (SmPC); key contra indications are: -- Hypersensitivity to the active substance or to any of the excipients listed in SmPC section 6.1. -- Lesion or condition at significant risk of major bleeding -- Concomitant treatment with any other anticoagulant agent -- Clinically significant active bleeding -- Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C -- Pregnancy and breast feeding
Many locations, France
E-mail: [email protected]
Phone: Not Available
Satisfaction and Quality of Life in patients with a diagnosis of non valvular atrial fibrillation who take Rivaroxaban for Stroke Prevention